去纤苷在中国哪里买的到？

For some patients with leukemia and lymphoma, hematopoietic stem transplantation (HSCT) is the disease and the only hope to regain health. Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem transplantation (HSCT), and the mortality rate of severe HVOD can be as high as 100%. (Defibrotide, produced in Italy) is a single-stranded oligonucleotide mixture that has anti-thrombotic and fibrinolytic effects. In recent years, multiple research results have shown that defibrotide is safe and effective in preventing and treating HVOD. DEFITELIO is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT). 

On March 30, 2016, the FDA approved the marketing of Jazz Pharmaceuticals’ Defibrotide sodium (Defitelio) for the treatment of adult and pediatric patients with hepatic venular occlusion (VOD) and renal or lung abnormalities after blood or bone marrow hematopoietic stem cell transplantation (HSCT). Hepatic venule occlusion causes edema and reduced blood flow in the liver due to blockage of some blood vessels in the liver. This condition can lead to the most severe liver damage. The drug is the first drug approved by the FDA for the treatment of severe hepatic venous occlusion, a rare and fatal liver disease. 

Defibrotide has received marketing authorization from the European Commission for the treatment of severe hepatic VOD in hematopoietic stem cell transplantation (HSCT). A phase 3 randomized controlled trial of defibrination to prevent hepatic VOD in pediatric transplant patients has also been completed. Defibrotide has been generally well tolerated; the most common adverse reactions observed during premarketing use to treat hepatic VOD were bleeding, hypotension, and coagulopathy. 

For domestic patients, defibrotide is relatively far away from us because defibrotide is not on the market in China. Patients can purchase it in European and American countries where it is already on the market.